Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967870 | 1.00 | HTR2A (0.72) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL29543607 | 0.91 | HTR2A (0.58) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970928 | 0.91 | HTR2A (0.58) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970977 | 0.90 | HTR2A (0.67) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL29543596 | 0.90 | HTR2A (0.67) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970959 | 0.89 | HTR2A (0.59) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970860 | 0.87 | HTR2A (0.74) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL29633103 | 0.87 | HTR2A (0.74) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL1119068 | 0.85 | HTR2A (1.00) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970970 | 0.82 | HTR2A (0.93) | HTR2AHTR2CHTR2BKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250179042-A1 | USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250129037-A1 | FLUORINATED EMPATHOGENS | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-12257258-B2 | Tryptamine compositions for enhancing neurite outgrowth | TURTLE BEAR HOLDINGS, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-12221428-B2 | Use of deuterated empathogens as therapeutic agents | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-12180176-B2 | Fluorinated empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-11622971-B2 | — | — | 2023-04-11 | — | — | US | disclosed |
| WO-2023028092-A2 | FLUORINATED EMPATHOGENS | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023028091-A1 | DEUTERATED EMPATHOGENS | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220370483-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC | 2022-11-24 | — | — | US | disclosed |
| WO-2022236130-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220125809-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2021101926-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | STAMETS PAUL EDWARD (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129037-A1 | FLUORINATED EMPATHOGENS | SLC18A2, BDNF, GAP43 | HTR2A 13/4885HTR2C 49/4885HTR2B 38/4885 |
| US-12180176-B2 | Fluorinated empathogens | SLC18A2, BDNF, GAP43 | HTR2A 13/4885HTR2C 49/4885HTR2B 38/4885 |
| US-20210251976-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885 |
| US-20250179042-A1 | USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS | SLC18A2, SLC6A3, GAP43 | HTR2A 47/4885HTR2C 115/4885HTR2B 83/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885 |
| US-12403150-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885 |
| US-20220370483-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | MAOB, TPSG1, TPSB2 | HTR2A 18/4885HTR2C 14/4885HTR2B 11/4885 |
| US-12257258-B2 | Tryptamine compositions for enhancing neurite outgrowth | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885 |
| US-20260048048-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 7/4885HTR2C 4/4885HTR2B 5/4885 |
| US-20220160737-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885 |
| US-20250325533-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, BDNF, HTR6 | HTR2A 9/4885HTR2C 7/4885HTR2B 8/4885 |
| US-12221428-B2 | Use of deuterated empathogens as therapeutic agents | SLC18A2, SLC6A3, GAP43 | HTR2A 47/4885HTR2C 115/4885HTR2B 83/4885 |
| US-20220125809-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885 |
| US-20250205254-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR2C 6/4885HTR2B 9/4885 |
| US-20260108544-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 9/4885HTR2C 5/4885HTR2B 8/4885 |
| US-11622971-B2 | — | HTR6, HTR1B, BDNF | HTR2A 7/4885HTR2C 4/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.